Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
J&J seeks EU approval of nipocalimab to treat people living with generalised myasthenia gravis
Janssen-Cilag International NV submitted an MAA to the EMA for nipocalimab, seeking approval for treating generalized myasthenia gravis (gMG). The phase 3 Vivacity-MG3 study showed nipocalimab plus standard of care (SOC) outperformed placebo plus SOC in improving MG-ADL scores. Nipocalimab is the first FcRn blocker to demonstrate sustained disease control in gMG subtypes, with safety and tolerability consistent with previous studies.
RYBREVANT® (amivantamab) plus chemotherapy shows positive
Updated MARIPOSA-2 study results show amivantamab plus chemotherapy significantly improves post-progression outcomes and overall survival in previously treated NSCLC patients with EGFR exon 19 deletions or L858R mutations, compared to chemotherapy alone.
RYBREVANT® (amivantamab) plus chemotherapy shows positive overall survival trend
Janssen-Cilag International NV announced updated Phase 3 MARIPOSA-2 study results showing RYBREVANT® (amivantamab) plus chemotherapy significantly improved post-progression outcomes and overall survival in previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 19 deletions or L858R mutations, compared to chemotherapy alone. The data were presented at the ESMO 2024 Congress.
Oncternal stock crashes by 60% as it lays off staff and scraps trials
Oncternal Therapeutics discontinues clinical trials for ONCT-534 and ONCT-808, leading to a 60% stock drop and 37% workforce reduction to save cash.
Driving Innovation in Cancer Care, Redefining Value, and Improving Patient Access
Experts at the Patient-Centered Oncology Care meeting discussed the impact of the Inflation Reduction Act (IRA) and Enhancing Oncology Model (EOM) on cancer care, focusing on access, innovation, and value. The IRA's shortened exclusivity periods for small molecules and changes in benefit design were highlighted, along with concerns about formulary management and drug shortages. The EOM's shift in Medicare's share of total costs and its potential to exacerbate disparities were also debated, with calls for redefining value in oncology to better support high-cost, high-value therapies.
Cidara axes 30% of staff to focus on flu prevention drug
Cidara Therapeutics plans to lay off 30% of its workforce to fund the clinical development of its reacquired flu candidate, CD388, which will enter a Phase IIb trial in Q3. The company reacquired the rights from Johnson & Johnson for $85m after J&J deprioritized the drug's development.
FDA Roundup: Apple AirPods Hearing Aids, Tremfya for Ulcerative Colitis
FDA approves OTC hearing aid software for Apple AirPods, based on study with 118 adults showing comparable performance to professional aids. Also, FDA approves Tremfya for active ulcerative colitis, with 50% of patients achieving clinical remission. Additionally, plozasiran receives FDA breakthrough therapy designation for familial chylomicronemia syndrome.
Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University
The 'Clinical Trials: Psychedelic Therapeutics' report reviews global trials, highlighting non-industry sponsors leading (58%), Yale University as top non-industry, Johnson & Johnson as top industry, and CNS as top therapy area (92%). The US leads in trials, and Phase II trials dominate since 2013.
Psychedelic Therapeutics Clinical Trials Research Report
The 'Clinical Trials: Psychedelic Therapeutics' report reviews global trials, highlighting non-industry sponsors leading (58%), with Yale University and Johnson & Johnson as top sponsors. Central nervous system trials dominate (92%), with depression as the top indication. The US leads in North American studies, and Phase II trials have outnumbered others since 2013.
7MM Migraine Drug Market Forecast and Analysis to 2033
The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.
© Copyright 2025. All Rights Reserved by MedPath